Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration

Peter Teismann, K. Tieu, D. -. K. Choi, D. C. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, S. Przedborski

Research output: Contribution to journalArticle

517 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder of uncertain pathogenesis characterized by the loss of the nigrostriatal dopaminergic neurons, which can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Increased expression of cyclooxygenase type 2 (COX-2) and production of prostaglandin E-2 have been implicated in neurodegeneration in several pathological settings. Here we show that COX-2, the rate-limiting enzyme in prostaglandin E2 synthesis, is up-regulated in brain dopaminergic neurons of both PD and MPTP mice. COX-2 induction occurs through a JNK/c-Jun-dependent mechanism after MPTP administration. We demonstrate that targeting COX-2 does not protect against MPTP-induced dopaminergic neurodegeneration by mitigating inflammation. Instead, we provide evidence that COX-2 inhibition prevents the formation of the oxidant species dopamine-quinone, which has been implicated in the pathogenesis of PD. This study supports a critical role for COX-2 in both the pathogenesis and selectivity of the PD neurodegenerative process. Because of the safety record of the COX-2 inhibitors, and their ability to penetrate the blood-brain barrier, these drugs may be therapies for PD.

Original languageEnglish
Pages (from-to)5473-5478
Number of pages5
JournalPNAS
Volume100
Issue number9
Early online date17 Apr 2003
DOIs
Publication statusPublished - 29 Apr 2003

Keywords

  • nitric-oxide
  • mouse model
  • mptp
  • prostaglandin
  • expression
  • dopamine
  • neurons
  • kinase
  • oxidation
  • mechanism

Cite this

Teismann, P., Tieu, K., Choi, D. . K., Wu, D. C., Naini, A., Hunot, S., ... Przedborski, S. (2003). Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration. PNAS, 100(9), 5473-5478. https://doi.org/10.1073/pnas.0837397100

Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration. / Teismann, Peter; Tieu, K.; Choi, D. -. K.; Wu, D. C.; Naini, A.; Hunot, S.; Vila, M.; Jackson-Lewis, V.; Przedborski, S.

In: PNAS, Vol. 100, No. 9, 29.04.2003, p. 5473-5478.

Research output: Contribution to journalArticle

Teismann, P, Tieu, K, Choi, DK, Wu, DC, Naini, A, Hunot, S, Vila, M, Jackson-Lewis, V & Przedborski, S 2003, 'Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration' PNAS, vol. 100, no. 9, pp. 5473-5478. https://doi.org/10.1073/pnas.0837397100
Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S et al. Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration. PNAS. 2003 Apr 29;100(9):5473-5478. https://doi.org/10.1073/pnas.0837397100
Teismann, Peter ; Tieu, K. ; Choi, D. -. K. ; Wu, D. C. ; Naini, A. ; Hunot, S. ; Vila, M. ; Jackson-Lewis, V. ; Przedborski, S. / Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration. In: PNAS. 2003 ; Vol. 100, No. 9. pp. 5473-5478.
@article{7616a61590954fc58638199d2cf225b7,
title = "Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration",
abstract = "Parkinson's disease (PD) is a neurodegenerative disorder of uncertain pathogenesis characterized by the loss of the nigrostriatal dopaminergic neurons, which can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Increased expression of cyclooxygenase type 2 (COX-2) and production of prostaglandin E-2 have been implicated in neurodegeneration in several pathological settings. Here we show that COX-2, the rate-limiting enzyme in prostaglandin E2 synthesis, is up-regulated in brain dopaminergic neurons of both PD and MPTP mice. COX-2 induction occurs through a JNK/c-Jun-dependent mechanism after MPTP administration. We demonstrate that targeting COX-2 does not protect against MPTP-induced dopaminergic neurodegeneration by mitigating inflammation. Instead, we provide evidence that COX-2 inhibition prevents the formation of the oxidant species dopamine-quinone, which has been implicated in the pathogenesis of PD. This study supports a critical role for COX-2 in both the pathogenesis and selectivity of the PD neurodegenerative process. Because of the safety record of the COX-2 inhibitors, and their ability to penetrate the blood-brain barrier, these drugs may be therapies for PD.",
keywords = "nitric-oxide, mouse model, mptp, prostaglandin, expression, dopamine, neurons, kinase, oxidation, mechanism",
author = "Peter Teismann and K. Tieu and Choi, {D. -. K.} and Wu, {D. C.} and A. Naini and S. Hunot and M. Vila and V. Jackson-Lewis and S. Przedborski",
year = "2003",
month = "4",
day = "29",
doi = "10.1073/pnas.0837397100",
language = "English",
volume = "100",
pages = "5473--5478",
journal = "PNAS",
issn = "0027-8424",
publisher = "NATL ACAD SCIENCES",
number = "9",

}

TY - JOUR

T1 - Cyclooxygenase-2 is instrumental in Parkinson disease neurodegeneration

AU - Teismann, Peter

AU - Tieu, K.

AU - Choi, D. -. K.

AU - Wu, D. C.

AU - Naini, A.

AU - Hunot, S.

AU - Vila, M.

AU - Jackson-Lewis, V.

AU - Przedborski, S.

PY - 2003/4/29

Y1 - 2003/4/29

N2 - Parkinson's disease (PD) is a neurodegenerative disorder of uncertain pathogenesis characterized by the loss of the nigrostriatal dopaminergic neurons, which can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Increased expression of cyclooxygenase type 2 (COX-2) and production of prostaglandin E-2 have been implicated in neurodegeneration in several pathological settings. Here we show that COX-2, the rate-limiting enzyme in prostaglandin E2 synthesis, is up-regulated in brain dopaminergic neurons of both PD and MPTP mice. COX-2 induction occurs through a JNK/c-Jun-dependent mechanism after MPTP administration. We demonstrate that targeting COX-2 does not protect against MPTP-induced dopaminergic neurodegeneration by mitigating inflammation. Instead, we provide evidence that COX-2 inhibition prevents the formation of the oxidant species dopamine-quinone, which has been implicated in the pathogenesis of PD. This study supports a critical role for COX-2 in both the pathogenesis and selectivity of the PD neurodegenerative process. Because of the safety record of the COX-2 inhibitors, and their ability to penetrate the blood-brain barrier, these drugs may be therapies for PD.

AB - Parkinson's disease (PD) is a neurodegenerative disorder of uncertain pathogenesis characterized by the loss of the nigrostriatal dopaminergic neurons, which can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Increased expression of cyclooxygenase type 2 (COX-2) and production of prostaglandin E-2 have been implicated in neurodegeneration in several pathological settings. Here we show that COX-2, the rate-limiting enzyme in prostaglandin E2 synthesis, is up-regulated in brain dopaminergic neurons of both PD and MPTP mice. COX-2 induction occurs through a JNK/c-Jun-dependent mechanism after MPTP administration. We demonstrate that targeting COX-2 does not protect against MPTP-induced dopaminergic neurodegeneration by mitigating inflammation. Instead, we provide evidence that COX-2 inhibition prevents the formation of the oxidant species dopamine-quinone, which has been implicated in the pathogenesis of PD. This study supports a critical role for COX-2 in both the pathogenesis and selectivity of the PD neurodegenerative process. Because of the safety record of the COX-2 inhibitors, and their ability to penetrate the blood-brain barrier, these drugs may be therapies for PD.

KW - nitric-oxide

KW - mouse model

KW - mptp

KW - prostaglandin

KW - expression

KW - dopamine

KW - neurons

KW - kinase

KW - oxidation

KW - mechanism

U2 - 10.1073/pnas.0837397100

DO - 10.1073/pnas.0837397100

M3 - Article

VL - 100

SP - 5473

EP - 5478

JO - PNAS

JF - PNAS

SN - 0027-8424

IS - 9

ER -